Saikosaponin B1

Saikosaponin B1 at a Glance

Saikosaponin B1 (SSb1) is an oleanane triterpenoid saponin of Bupleurum (chai hu) root, and one of the “b-series” congeners of the better-known saikosaponin a / saikosaponin d trio. Its defining fact is chemical: unlike those native saponins, saikosaponin B1 is largely a secondary product — it forms when saikosaponin a’s strained 13,28-epoxide is rearranged by acid and heat (during traditional vinegar-baking, or in the gut) into a more stable heteroannular diene ^{6Reference 6Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}.

That origin colours everything about the molecule. Because it is generated by the same processing that lowers the toxicity of raw Bupleurum, it sits on the milder side of the saikosaponin family, and its own pharmacology is read on its own terms. The most consistent preclinical signal is antifibrotic / liver-protective, reported in three independent mouse/cell studies with different mechanisms ^{1,2,3Reference 1Wang G et al. · 2026Saikosaponin B1 alleviates hepatic fibrosis by targeting the LDHA-MCT1/4 axis to inhibit lactate-driven profibrogenic signalingView study →Reference 2Shao M et al. · 2025Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing Gli1 degradationView study →Reference 3Dong H et al. · 2023Nanodrug rescues liver fibrosis via synergistic therapy with H₂O₂ depletion and saikosaponin b1 sustained releaseView study →}; there is also anti-inflammatory (acute lung injury) and Hedgehog-blocking anticancer data ^{4,5Reference 4Niu Y et al. · 2025Integrative network pharmacology and multi-omics analysis reveal key targets and mechanisms of saikosaponin B1 against acute lung injuryView study →Reference 5Luo J et al. · 2022AnimalSaikosaponin B1 and saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathwayView study →}.

The honest headline: all of it is preclinical, there are no human trials of the isolate, and — despite the class’s anti-influenza reputation — saikosaponin B1 itself was among the inactive saponins when a Bupleurum extract was screened against influenza ^{8Reference 8Fang W et al. · 2016Fang W, et al. (2016). [Triterpenoid saponins from Bupleurum marginatum var. stenophyllum]. Zhongguo Zhong Yao Za Zhi (China Journal of Chinese Materia Medica). https://pubmed.ncbi.nlm.nih.gov/28879740/View study →}. Any real-world exposure is only as a minor, processing-dependent fraction of the whole herb.

Saikosaponin B1 vs. Saikosaponin A

This is the section that only this molecule needs, and the key to reading its literature. The native, abundant saponin in fresh Bupleurum root is saikosaponin a (a “type I” saikosaponin), which carries a strained 13β,28-epoxy (allyl-oxide) bridge. That bridge is acid-labile: under acidic, heated conditions — dilute acid in the lab, traditional vinegar/wine frying of the root, or gastric and gut-microbial exposure after ingestion — the epoxide ring opens and rearranges into a heteroannular diene (a “type II” saikosaponin, with the diene’s characteristic UV absorption near 242–263 nm). Saikosaponin B1 is one of the products of that rearrangement; saikosaponin B2 is a C-16 epimer of it, and saikosaponin G is a related isomer ^{6Reference 6Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}.

Two consequences follow, and both matter when reading claims about this molecule:

• It is partly an artifact. A “saikosaponin B1” content figure depends heavily on how the material was grown, dried, processed and stored — the same sample can gain B-series saponins on heating. Some of what is attributed to SSb1 in a decoction reflects processing chemistry, not the fresh plant.
• It is the milder half of the conversion. The acid/heat processing that generates the b-series is the same step traditionally used to reduce Bupleurum’s cardio- and hepatotoxicity, because it lowers the content of the SERCA-inhibiting saikosaponin a and d ^{9Reference 9Wang S et al. · 2017Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →}. Saikosaponin B1 does not carry saikosaponin a’s documented SERCA-inhibition organ toxicity, and it is reported as less cytotoxic than the parent saponins ^{10Reference 10Yang Y et al. · 2025Research progress on the extraction, purification, biotransformation, pharmacological effects, toxicity, combined therapy and new dosage forms of saikosaponinsView study →} — which is exactly why the page below treats it as a lower-hazard molecule than its siblings.

What It's Used For

Saikosaponin B1’s evidence is entirely preclinical and clusters in three areas. The strongest, by weight of independent studies, is antifibrotic liver protection.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. No human isolate data exist, so scores stay modest by design.

01Antifibrotic / Liver ProtectionShaky40%Three independent mouse/cell studies, distinct mechanisms ^{1,2,3Reference 1Wang G et al. · 2026Saikosaponin B1 alleviates hepatic fibrosis by targeting the LDHA-MCT1/4 axis to inhibit lactate-driven profibrogenic signalingView study →Reference 2Shao M et al. · 2025Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing Gli1 degradationView study →Reference 3Dong H et al. · 2023Nanodrug rescues liver fibrosis via synergistic therapy with H₂O₂ depletion and saikosaponin b1 sustained releaseView study →}

02Anti-Inflammatory (Acute Lung Injury)Shaky28%One LPS mouse model + multi-omics ^{4Reference 4Niu Y et al. · 2025Integrative network pharmacology and multi-omics analysis reveal key targets and mechanisms of saikosaponin B1 against acute lung injuryView study →}

03Anticancer (Hedgehog / Medulloblastoma)Shaky24%One allograft mouse study + SMO IC₅₀ ^{5Reference 5Luo J et al. · 2022AnimalSaikosaponin B1 and saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathwayView study →}

Mechanisms

Pharmacokinetics

Saikosaponin B1 behaves like the large triterpenoid glycoside it is: poorly absorbed intact. The classic study administered it orally to conventional, germ-free and Eubacterium sp. A-44-infected gnotobiote rats and found that meaningful absorption depends on intestinal bacteria hydrolysing the sugar chains, converting the saponin to prosaikogenin A and then the aglycone saikogenin A — the forms that actually cross the gut wall; germ-free animals lacking that flora handle it very differently ^{11Reference 11Kida H et al. · 1998AnimalMetabolism and pharmacokinetics of orally administered saikosaponin b1 in conventional, germ-free and Eubacterium spView study →}. Two practical implications follow. First, oral bioavailability of the intact molecule is low and microbiome-dependent, so exposures used in the in-vitro/injected studies above are unlikely to be reproduced by ordinary oral herb intake. Second, saikosaponin B1 is itself already a downstream rearrangement product, and it continues down the hydrolysis chain to its genin in vivo — the “active” species after an oral dose may be the metabolites, not SSb1 as dosed. No human pharmacokinetic study of the isolate exists.

Clinical Trials

There are no human trials of isolated saikosaponin B1. All Bupleurum clinical experience is with the whole herb or a multi-herb formula (e.g. Xiao Chai Hu Tang / Sho-saiko-to), which cannot be attributed to this single, largely processing-derived saponin.

Last checked: July 2026.

Isolate vs. Plant Studies

Every finding above used the isolated molecule — dosed orally or intraperitoneally in mice, or applied to cultured hepatic stellate / tumour cells — which is a genuine strength for attribution: these are saikosaponin B1’s own effects, not the whole herb’s. The transferability caveat runs the other way. Because SSb1 is partly a processing artifact of saikosaponin a ^{7Reference 7Wang Z et al. · 2021Facile synthesis of saikosaponinsView study →} and is poorly absorbed unless gut bacteria hydrolyse it ^{11Reference 11Kida H et al. · 1998AnimalMetabolism and pharmacokinetics of orally administered saikosaponin b1 in conventional, germ-free and Eubacterium spView study →}, the isolate results do not straightforwardly predict what a Bupleurum decoction does — the whole-herb effect is a moving mixture of native and processing-derived saponins plus their microbial metabolites. Conversely, Bupleurum’s human/clinical reputation belongs to the whole herb and cannot be reassigned to this congener; indeed, when a Bupleurum saponin set was screened against influenza, the active members were other saikosaponins and saikosaponin B1 was not among them ^{8Reference 8Fang W et al. · 2016Fang W, et al. (2016). [Triterpenoid saponins from Bupleurum marginatum var. stenophyllum]. Zhongguo Zhong Yao Za Zhi (China Journal of Chinese Materia Medica). https://pubmed.ncbi.nlm.nih.gov/28879740/View study →}.

Prevalence in Nature

Saikosaponin B1 is confined, as far as the pharmacological literature goes, to the genus Bupleurum (chai hu) — the same oleanane-triterpenoid-saponin family that Ashour and Wink catalogued across the genus, where the saikosaponins total roughly 2–8% of dry root and members a, c and d dominate the native profile ^{12Reference 12Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}. Saikosaponin B1 is a minor component of that profile and, distinctively, is not primarily a stored metabolite: it accumulates when the acid-labile saikosaponin a is rearranged by heat and acid — during drying, decoction, and especially traditional vinegar/wine processing of the root — so its measured level reflects both the plant and how the material was handled ^{6,9Reference 6Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →Reference 9Wang S et al. · 2017Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →}. Because of that, a clean ”% dry weight in the fresh root” figure is not well defined for this molecule; the honest statement is that it is a low-abundance, processing-enriched saikosaponin rather than a headline constituent.

Discovery & Synthesis

Saikosaponin B1 entered the literature as one of the “b-series” saikosaponins — the secondary saponins recognised once chemists realised that Bupleurum’s native “a-series” saponins rearrange on acid and heat. Its structural origin is now well characterised: under acidic hydrolytic conditions, saikosaponin a’s 13β,28-epoxy (allyl-oxide) ring is protonated and opened, and the molecule rearranges into a heteroannular diene, yielding saikosaponin B1 (together with the C-16 epimer saikosaponin B2 and the related saikosaponin G) ^{6Reference 6Li J et al. · 2016Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditionsView study →}. It is therefore best thought of as a semi-natural compound: present in processed herb and formed in the gut, but produced in the lab by controlled acid treatment of the parent saponin rather than by total synthesis. The parent a/d saikosaponins were themselves first totally synthesised only in 2021, built up from oleanolic acid via gold(I)-catalysed glycosylation ^{7Reference 7Wang Z et al. · 2021Facile synthesis of saikosaponinsView study →} — but saikosaponin B1 itself is not made that way: a dedicated total synthesis of it is not well documented, and research material is obtained by extraction from processed Bupleurum or by acid conversion of saikosaponin a (CAS 58558-08-0).

Patents: not yet researched.

Toxicity & Safety

Saikosaponin B1 carries a low flag — the same call as its mild sibling saikosaponin c, and one step below saikosaponin a and d (moderate). The reasoning is specific: SSb1 is the product of the detoxifying acid/heat processing, it lacks saikosaponin a’s documented SERCA-inhibition cardio-/hepatotoxicity and saikosaponin d’s dose-dependent hepatotoxicity, it is reported as less cytotoxic than the parent saponins ^{10Reference 10Yang Y et al. · 2025Research progress on the extraction, purification, biotransformation, pharmacological effects, toxicity, combined therapy and new dosage forms of saikosaponinsView study →}, and it is itself studied as an anti-fibrotic, liver-protective agent ^{1,2Reference 1Wang G et al. · 2026Saikosaponin B1 alleviates hepatic fibrosis by targeting the LDHA-MCT1/4 axis to inhibit lactate-driven profibrogenic signalingView study →Reference 2Shao M et al. · 2025Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing Gli1 degradationView study →}. The badge is not a clean bill of health, though — the residual cautions below are class-level and reflect how little the isolate has been safety-tested.

Safety at a Glance

✅ Low / no toxicity

• The milder, processing-derived saikosaponin. Lacks saikosaponin a’s SERCA-driven organ toxicity and is reported less cytotoxic than the parent saponins.
• No dedicated isolate safety dataset. Efficacy work is preclinical; there is no repeat-dose, genotoxicity or human safety package for saikosaponin B1 specifically.
• Oleanane saponins are hemolytic at high concentration. A generic class property that applies to any triterpenoid saponin.
• Travels with hepatotoxic company. It is a Bupleurum saponin, and Bupleurum formulas (e.g. Sho-saiko-to) carry formula-level hepatotoxicity and interstitial-pneumonia reports.
• Avoid in pregnancy. Bupleurum is not recommended in pregnancy and there are no reproductive-safety data for this saponin — a decision that belongs to the herb/formula, not the isolate.

Full Safety & Interactions Detail

Saikosaponin B1’s low grading is a relative judgement within the saikosaponin family, made on the same basis as saikosaponin c. The molecule-specific hazard that pushes saikosaponin a and d to moderate — SERCA (Ca²⁺-ATPase) inhibition and dose-dependent hepatotoxicity — is not documented for the b-series, and the very acid/heat processing that generates saikosaponin B1 is the traditional step used to lower Bupleurum’s toxicity by reducing SSa/SSd content ^{9Reference 9Wang S et al. · 2017Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →}.

Saikosaponin B1 is also reported as less cytotoxic than its parent saponins ^{10Reference 10Yang Y et al. · 2025Research progress on the extraction, purification, biotransformation, pharmacological effects, toxicity, combined therapy and new dosage forms of saikosaponinsView study →}, and its own preclinical activity is liver-protective rather than injurious ^{1,2Reference 1Wang G et al. · 2026Saikosaponin B1 alleviates hepatic fibrosis by targeting the LDHA-MCT1/4 axis to inhibit lactate-driven profibrogenic signalingView study →Reference 2Shao M et al. · 2025Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing Gli1 degradationView study →}.

That said, three cautions remain and none has been resolved for the isolate. (1) As an oleanane triterpenoid saponin, it shares the class property of haemolysis at high concentration. (2) It occurs only in Bupleurum, whose multi-herb formulas carry well-known hepatotoxicity and interstitial-pneumonia reports at the formula level — a context caution, not a demonstrated SSb1 effect ^{9,12Reference 9Wang S et al. · 2017Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix BupleuriView study →Reference 12Ashour ML · 2011ReviewGenus Bupleurum: a review of its phytochemistry, pharmacology and modes of actionView study →}.

(3) There is no dedicated toxicology package for saikosaponin B1 — no repeat-dose, reproductive or genotoxicity study of the isolate — so the low badge rests on relative pharmacology and structural reasoning, not on a clean safety dataset. No drug-interaction study (CYP/transporter) of the isolate has been reported. Pregnancy/lactation decisions belong to the herb or product page where intake is decided; stated here only as the finding that Bupleurum is traditionally avoided in pregnancy and no reproductive-safety data exist for this saponin.

Dosage

There is no established or safe human dose for saikosaponin B1 — it has never been given as an isolate to humans. Every figure in the literature is a preclinical concentration or animal dose: cell-assay IC₅₀ values (e.g. ≈242 nM against Hedgehog signalling) and rodent doses such as 30 mg/kg intraperitoneally in the medulloblastoma model ^{5Reference 5Luo J et al. · 2022AnimalSaikosaponin B1 and saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathwayView study →}, neither of which translates to an oral human dose — especially given that the intact saponin is poorly absorbed and needs gut-bacterial hydrolysis to enter the body ^{11Reference 11Kida H et al. · 1998AnimalMetabolism and pharmacokinetics of orally administered saikosaponin b1 in conventional, germ-free and Eubacterium spView study →}. Any real-world exposure is only as a minor, processing-dependent fraction of whole chai hu root or formula. These are doses studied in research and are not a personal recommendation.

References

1. Wang G, et al. (2026). Saikosaponin B1 alleviates hepatic fibrosis by targeting the LDHA-MCT1/4 axis to inhibit lactate-driven profibrogenic signaling. Naunyn-Schmiedeberg’s Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/42012661/
2. Shao M, et al. (2025). Saikosaponin b1 attenuates liver fibrosis by blocking STAT3/Gli1 interaction and inducing Gli1 degradation. Exploration (Beijing). https://pubmed.ncbi.nlm.nih.gov/41163803/
3. Dong H, et al. (2023). Nanodrug rescues liver fibrosis via synergistic therapy with H₂O₂ depletion and saikosaponin b1 sustained release. Communications Biology. https://pubmed.ncbi.nlm.nih.gov/36797395/
4. Niu Y, et al. (2025). Integrative network pharmacology and multi-omics analysis reveal key targets and mechanisms of saikosaponin B1 against acute lung injury. Metabolites. https://pubmed.ncbi.nlm.nih.gov/41441024/
5. Luo J, et al. (2022). Saikosaponin B1 and saikosaponin D inhibit tumor growth in medulloblastoma allograft mice via inhibiting the Hedgehog signaling pathway. Journal of Natural Medicines. https://pubmed.ncbi.nlm.nih.gov/35171398/
6. Li J, Xu Q, Jiang H (2016). Identification and characterization of two new degradation products of saikosaponin A under acid hydrolytic conditions. Molecules. https://pubmed.ncbi.nlm.nih.gov/27649123/
7. Wang Z, Wei B, Mu T, Xu P, Yu B (2021). Facile synthesis of saikosaponins. Molecules. https://pubmed.ncbi.nlm.nih.gov/33808330/
8. Fang W, et al. (2016). [Triterpenoid saponins from Bupleurum marginatum var. stenophyllum]. Zhongguo Zhong Yao Za Zhi (China Journal of Chinese Materia Medica). https://pubmed.ncbi.nlm.nih.gov/28879740/
9. Wang S, Zhang Y, Zhang Q, et al. (2017). Content decline of the SERCA inhibitors saikosaponin A and D attenuates the cardiotoxicity and hepatotoxicity of vinegar-baked Radix Bupleuri. Environmental Toxicology and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/28412648/
10. Yang Y, Chen H, Sun J, et al. (2025). Research progress on the extraction, purification, biotransformation, pharmacological effects, toxicity, combined therapy and new dosage forms of saikosaponins. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/40639699/
11. Kida H, et al. (1998). Metabolism and pharmacokinetics of orally administered saikosaponin b1 in conventional, germ-free and Eubacterium sp. A-44-infected gnotobiote rats. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/9657043/
12. Ashour ML, Wink M (2011). Genus Bupleurum: a review of its phytochemistry, pharmacology and modes of action. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/21749378/

View all 12 references▾